NeuroOne® Announces Preliminary Unaudited First Quarter Fiscal 2025 Revenue Increase to a Record $6.2 Million

Core Viewpoint - NeuroOne Medical Technologies Corporation reported a significant increase in revenue for the first quarter of fiscal 2025, driven by collaboration revenue and product sales, indicating strong growth potential in the medical technology sector focused on neurological disorders [1][2][3]. Revenue Highlights - Total revenue for the first quarter of fiscal 2025 is expected to reach a record $6.2 million, a substantial increase from$1.0 million in the same quarter of fiscal 2024 [2]. - The revenue includes a one-time upfront payment of $3.0 million from a collaboration with Zimmer Biomet, which is part of an expanded distribution agreement for the OneRF™ Ablation System [2][4]. - Product revenues are projected to increase by 227$3.2 million in the first quarter of fiscal 2025, compared to $1.0 million in the first quarter of fiscal 2024 [3]. Future Guidance - For the full fiscal year 2025, the company maintains its guidance for product revenues, excluding collaboration revenues, to be between$8.0 million and $10.0 million, with product gross margins expected to range from 47% to 51% [3]. Business Operations - The increase in expected revenue is attributed to higher-than-anticipated product sales as the partner, Zimmer Biomet, builds inventory and implements NeuroOne's products and technology with customers [4]. - A virtual investor webinar is scheduled to discuss business operations and recent updates, including the collaboration with Zimmer Biomet [5][6]. Company Overview - NeuroOne Medical Technologies Corporation focuses on developing minimally invasive and high-definition solutions for neurological disorders, aiming to improve patient outcomes and reduce procedural costs [8].